Literature DB >> 10697539

Dietary beta-carotene and astaxanthin but not canthaxanthin stimulate splenocyte function in mice.

B P Chew1, M W Wong, J S Park, T S Wong.   

Abstract

The in vivo modulatory effect of beta-carotene, astaxanthin and canthaxanthin on lymphocyte function was investigated. Female BALB/c mice (8 wk old) were fed a basal diet containing 0, 0.1% or 0.4% beta-carotene, astaxanthin or canthaxanthin for 0, 2 or 4 wk (n = 8/diet/period). Splenic lymphocytes were isolated and mitogen-stimulated proliferation, IL-2 production and lymphocyte cytotoxicity were assessed. Body weight and feed intake were not different among dietary treatments. Plasma carotenoids were undetectable in unsupplemented mice but concentrations of the respective carotenoids were elevated in mice fed 0.1 or 0.4% beta-carotene (0.22 and 0.39 mumol/L), astaxanthin (16.4 and 50.2 mumol/L) and canthaxanthin (5.00 and 7.02 mumol/L) respectively. Mice fed both dietary levels of beta-carotene and astaxanthin had enhanced phytohemagglutinin-induced lymphoblastogenesis compared to unsupplemented mice (P < 0.03). No treatment difference was detected with concanavalin A- or lipopolysaccharide-induced lympho-proliferation nor with IL-2 production (P < 0.05). Astaxanthin (0.1%) also enhanced lymphocyte cytotoxic activity (P < 0.08). In contrast, canthaxanthin did not significantly influence any of the lymphocyte functions measured. Results indicate that beta-carotene and astaxanthin but not canthaxanthin exert enhanced splenic lymphocyte function in mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10697539

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans.

Authors:  Jean Soon Park; Jong Hee Chyun; Yoo Kyung Kim; Larry L Line; Boon P Chew
Journal:  Nutr Metab (Lond)       Date:  2010-03-05       Impact factor: 4.169

2.  Therapeutic Potential of Astaxanthin in Diabetic Kidney Disease.

Authors:  Yuji Naito; Kazuhiko Uchiyama; Osamu Handa; Wataru Aoi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Astaxanthin uptake in domestic dogs and cats.

Authors:  Jean Soon Park; Hong Wook Kim; Bridget D Mathison; Michael G Hayek; Stefan Massimino; Gregory A Reinhart; Boon P Chew
Journal:  Nutr Metab (Lond)       Date:  2010-06-21       Impact factor: 4.169

Review 4.  Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.

Authors:  Haijian Wu; Huanjiang Niu; Anwen Shao; Cheng Wu; Brandon J Dixon; Jianmin Zhang; Shuxu Yang; Yirong Wang
Journal:  Mar Drugs       Date:  2015-09-11       Impact factor: 5.118

5.  Neuroprotective effect of astaxanthin against rat retinal ganglion cell death under various stresses that induce apoptosis and necrosis.

Authors:  Reiko Yamagishi; Makoto Aihara
Journal:  Mol Vis       Date:  2014-12-31       Impact factor: 2.367

Review 6.  Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oil.

Authors:  Marcelo P Barros; Sandra C Poppe; Eduardo F Bondan
Journal:  Nutrients       Date:  2014-03-24       Impact factor: 5.717

7.  Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca.

Authors:  Simona Destefanis; Daniela Giretto; Maria Cristina Muscolo; Alessandro Di Cerbo; Gianandrea Guidetti; Sergio Canello; Angela Giovazzino; Sara Centenaro; Giuseppe Terrazzano
Journal:  BMC Vet Res       Date:  2016-09-22       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.